Is Lancet paper on Covaxin efficacy missing something?

Even as paper stated efficacy of Covaxin is 77.8 per cent against symptomatic COVID and 65.2 per cent against Delta variant, health expert says trial did not take into account T-cells, important while determining efficacy of vaccine

The much-awaited data of the phase III trial of Bharat Biotech’s Covaxin has finally been released in international medical journal The Lancet, making it the first indigenous vaccine to have published the efficacy in public domain. But, is something missing from the report? Yes, says a Mumbai-based health expert.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!